Transition of PH patients from sildenafil to tadalafil: Feasibility and practical considerations

Lung

Volumn 190, Issue 5, 2012, Pages 573-578

  Shlobin, Oksana A ^a   Brown, A Whitney ^a   Weir, Nargues ^a   Ahmad, Shahzad ^a   Lemma, Merte ^a   Nathan, Steven D ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Pulmonary hypertension; Sildenafil; Tadalafil

Indexed keywords

AMBRISENTAN; BOSENTAN; PROSTACYCLIN; SILDENAFIL; TADALAFIL; UNIPROST;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FITNESS; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; WAKEFULNESS;

ADULT; AGED; CARBOLINES; EXERCISE TEST; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PIPERAZINES; PURINES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84866728530     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-012-9408-6     Document Type: Article

References (14)

1. McGoon M, Gutterman D, Steen V et al (2004) Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl): 14S-34S
2. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV (2007) Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131(6):1917-1928
3. Barst RJ, Gibbs JS, Ghofrani HA et al (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54(1):S78-S84
4. Galiè N, Ghofrani HA, Torbicki A et al (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353(20):2148-2157
5. Barst RJ, Oudiz RJ, Beardsworth A et al (2011) Tadalafil mono-therapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 30(6):632-643
6. Rubin LJ, Badesch DB, Fleming TR et al (2011) Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: SUPER-2. Chest 140(5):1274-1283
7. Wilkins MR, Wharton J, Grimminger F, Ghofrani HA (2008) Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 32(1):198-209
8. Francis SH, Sekhar KR, Ke H, Corbin JD (2011) Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds. Handb Exp Pharmacol 200:93-133
9. Castro PF, Greig D, Verdejo HE et al (2011) Intrapulmonary shunting associated with sildenafil treatment in a patient with idiopathic pulmonary arterial hypertension. Thorax66(12):1097-1098
10. Ghofrani HA, Voswinckel R, Reichenberger F et al (2004) Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 44(7):1488-1496
11. Du Boi RM, Weycker D, Albera C et al (2011) 6-Minute walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 183(9):1231-1237
12. Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schunemann HJ (2008) Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 32:637-643
13. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A (2009) A meta-analysis of randomised controlled trials in pulmonary arterial hypertension. Eur Heart J 30:394-403
14. Miyamoto S, Nagaya N, Satoh T et al (2000) Clinical correlates and prognostic significance of six minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161:487-492